UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: August 07, 2012
(Date of earliest event reported)

Corcept Therapeutics
(Exact name of registrant as specified in its charter)

DE	**000-50679**	**77-0487658**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

149 Commonwealth, Menlo Park CA	**94025**
(Address of principal executive offices)	(Zip Code)

(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition

On August 7, 2012, Corcept Therapeutics Incorporated (the "Company"), issued a press release announcing its financial results for the quarter ended June 30, 2012. The press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the information contained in the press release attached as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 and the information contained in the press release attached as Exhibit 99.1 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 7.01. Regulation FD Disclosure

On August 7, 2012, the Company issued a press release announcing its financial results for the quarter ended June 30, 2012. The press release is attached hereto as Exhibit 99.1.

The information in this Item 7.01 and the information contained in the press release attached as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01 and the information contained in the press release attached as Exhibit 99.1 is not incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in the filing unless specifically stated so therein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release of Corcept Therapeutics dated August 07, 2012

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 07, 2012

CORCEPT THERAPEUTICS

By: /s/ G. Charles Robb
G. Charles Robb
Chief Financial Officer

Exhibit Index

Exhibit No.	Description
99.1	Press Release of Corcept Therapeutics dated August 07, 2012

Corcept Therapeutics Announces Second Quarter Results and Corporate Update

MENLO PARK, CA -- (Marketwire - August 07, 2012) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financial results for the quarter ended June 30, 2012.

In April 2012, Corcept began offering its first medicine, Korlym™ (mifepristone) 300 mg Tablets as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Korlym is the first and only treatment approved by the United States Food and Drug Administration (FDA) for endogenous Cushing's syndrome.

"We are proud to have made Korlym available so quickly following FDA approval," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "Thanks to our commercial team's effective preparation, we were able to ship medicine without delay to patients with this debilitating, life-threatening illness. Our reimbursement team has helped assure that patients with Cushing's syndrome have access to the medicine by successfully communicating the benefits of Korlym to private and government insurers, who have promptly covered the use of Korlym in those patients."

"We made significant progress this quarter building our business platform," added Steven Lo, Corcept's Vice President of Commercial Operations. "We have now hired and begun training our initial force of medical science liaisons and the headquarters personnel we need to support commercialization. Our reimbursement team is in place and working successfully with payers. We were also able to take advantage of this June's Endocrine Society annual meeting to introduce Korlym to our target medical community."

Second Quarter Financial Results

Corcept reported a net loss of $7.6 million, or $0.09 per share, for the second quarter of 2012, compared to a net loss of $8.9 million, or $0.11 per share, for the second quarter of 2011.

For the second quarter of 2012, which was the first quarter with commercial sales of Korlym, Corcept recognized approximately $875,000 in net product sales, after deducting associated government rebates, chargebacks and other allowances.

"We are pleased that a geographically diverse group of physicians has already prescribed Korlym," said Dr. Belanoff, "and encouraged that many of these doctors were not investigators in our clinical study."

Operating expenses for the second quarter of 2012 were $8.5 million, compared to $8.9 million for the second quarter of 2011.

- Cost of sales for the second quarter of 2012 was $48,000, which consisted primarily of the cost of stability testing of product available for sale.

- Research and development expenses were $2.7 million for the second quarter of 2012, compared to $6.2 million for the comparable period in 2011. The decrease was primarily due to (i) lower consultancy costs, which were higher in 2011 when the company was preparing to submit and prosecute its New Drug Application for Korlym; (ii) decreased Korlym manufacturing costs, which before Korlym's approval in February 2012 were expensed as incurred due to the uncertainty of approval, but capitalized as inventory thereafter; and (iii) decreased clinical trial costs, as the extension of the company's phase 3 study of Korlym for Cushing's syndrome and its studies of CORT 108297 in healthy volunteers neared completion.

- Selling, general and administrative expenses were $5.8 million for the second quarter of 2012, compared to $2.7 million for the comparable period in 2011. This increase was primarily due to the additional staffing, consultancy costs and other professional service resources necessary to commercialize Korlym.

Corcept's cash balance as of June 30, 2012 was $34.9 million, as compared to $39.6 million at December 31, 2011, and reflects net proceeds of approximately $13.3 million from our March 2012 financing transaction and other warrant and option exercises, less approximately $18.0 million spent on operations during the first half of 2012. In addition, on July 6, 2012, the company raised approximately $46.1 million from the sale of common stock.

Recent Corporate Highlights

- Released Korlym for sale on April 10, less than eight weeks after FDA approval.
- Continued to build commercial infrastructure to support Korlym, including hiring medical science liaisons, medical affairs and marketing personnel.
- Submitted a supplemental NDA seeking to qualify a second Korlym tablet manufacturer.
- Raised $46.1 million from the sale of common stock to support increased research and development, pre-clinical and clinical activities.
- Began increasing from eight to 20 the number of clinical trial sites in the company's phase 3 trial of mifepristone for treatment of the psychotic features of psychotic depression.
- Accelerated research and development and pre-clinical work on the company's proprietary families of next-generation selective GR-II antagonists.

"While the launch of Korlym is our top priority," said Dr. Belanoff, "we are determined to extend our lead in medicines that block the activity of cortisol, a therapeutic approach with the potential to treat many serious illnesses. We are expanding our phase 3 study of mifepristone for the treatment of the psychotic features of psychotic depression and advancing to the clinic several of our next generation selective GR-II antagonists."

About Cushing's Syndrome

Endogenous Cushing's syndrome is caused by prolonged exposure of the body's tissues to high levels of the hormone cortisol and is generated by tumors that produce cortisol or ACTH. Cushing's syndrome is an orphan indication that most commonly affects adults aged 20 to 50. An estimated 10 to 15 of every one million people are newly diagnosed with this syndrome each year, resulting in over 3,000 new patients annually in the United States. An estimated 20,000 patients in the United States have Cushing's syndrome. Symptoms vary, but most people have one or more of the following manifestations: high blood sugar, diabetes, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are also common. Cushing's syndrome can affect every organ system in the body and can be lethal if not treated effectively.

About Korlym™ (mifepristone) 300 mg Tablets

Korlym blocks the glucocorticoid receptor type II (GR-II) to which cortisol normally binds, thereby inhibiting the effects of excess cortisol in Cushing's syndrome patients. On April 10, 2012, Corcept made Korlym available as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Korlym is the first and only FDA-approved treatment for that illness and the FDA has designated it as an Orphan Drug for that indication. Orphan Drug designation is a special status designed to encourage the development of medicines for rare diseases and conditions. Because Korlym is an Orphan Drug, Corcept will have marketing exclusivity for the approved indication in the United States until February 2019.

About Psychotic Depression

Psychotic depression is a serious psychiatric disorder that affects approximately three million people annually in the United States. It is more prevalent than either schizophrenia or bipolar I disorder. The disorder is characterized by severe depression accompanied by delusions, hallucinations or both. People with psychotic depression are approximately 70 times more likely to commit suicide than the general population and often require lengthy and expensive hospital stays. There is no FDA-approved treatment for psychotic depression.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. Korlym, a first generation GR-II antagonist, is the company's first FDA-approved medication. The company has a phase 3 trial underway for mifepristone for treatment of the psychotic features of psychotic depression and a portfolio of selective GR-II antagonists that block the effects of cortisol but not progesterone. It owns extensive intellectual property covering the use of GR-II antagonists, including mifepristone, in the treatment of a wide variety of metabolic and psychiatric disorders. It also holds composition of matter patents for its selective GR-II antagonists.

Statements made in this news release, other than statements of historical fact, are forward-looking statements. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements. For example, there can be no assurances regarding the pace of Korlym's acceptance by physicians and patients, the reimbursement decisions of government or private insurances, the amount of Korlym returned by customers, the FDA's response to the company's supplemental NDA, the effects of rapid technological change and competition, the protections afforded by Korlym's Orphan Drug Designation or by Corcept's other intellectual property rights, or the cost, pace and success of Corcept's product development efforts. These and other risks are set forth in the company's SEC filings, all of which are available from the company's website (**http://www.corcept.com**) or from the SEC's website (**http://www.sec.gov**). Corcept disclaims any intention or duty to update any forward-looking statement made in this news release.

CORCEPT THERAPEUTICS INCORPORATED
CONDENSED BALANCE SHEETS
(in thousands)

	June 30, 2012	December 31, 2011
	(Unaudited)	(Note)
ASSETS:		
Current assets:		
Cash and cash equivalents	$ 34,899	$ 39,635
Trade receivables, net	355	--
Inventory	2,437	--
Other current assets	608	140
Total current assets	38,299	39,775
Other assets	319	58
Total assets	$ 38,618	$ 39,833

LIABILITIES AND STOCKHOLDERS' EQUITY:		
Current liabilities:		
Accounts payable	$ 4,235	$ 3,611
Other current liabilities	1,555	1,415
Deferred revenue	26	--
Total current liabilities	5,816	5,026
Total stockholders' equity	32,802	34,807
Total liabilities and stockholders' equity	$ 38,618	$ 39,833

Note: Derived from audited financial statements at that date.

CORCEPT THERAPEUTICS INCORPORATED
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)

(Unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2012	2011	2012	2011
Revenues:				
Product sales, net	$ 875	$ --	$ 875	$ --
Operating expenses:				
Cost of sales	48	--	48	--
Research and development*	2,668	6,203	6,210	11,127
Selling, general and administrative*	5,751	2,666	13,238	4,840
Total operating expenses	8,467	8,869	19,496	15,967
Loss from operations	(7,592)	(8,869)	(18,621)	(15,967)
Interest and other income, net	--	(1)	--	1
Other expense	(5)	(12)	(9)	(17)
Net loss	$ (7,597)	$ (8,882)	$ (18,630)	$ (15,983)
Basic and diluted net loss per share	$ (0.09)	$ (0.11)	$ (0.22)	$ (0.19)
Shares used in computing basic and diluted net loss per share	88,621	84,010	86,521	82,396
*Includes non-cash stock-based compensation of the following:				
Research and development	$ 138	$ 267	$ 256	$ 323
Selling, general and administrative	744	602	3,015	1,126
Total non-cash stock-based compensation	$ 882	$ 869	$ 3,271	$ 1,449

CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
crobb@corcept.com
www.corcept.com